# A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

> **NCT03965013** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 78 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Healthy Volunteers

## Interventions

- **DRUG:** NNC0268-0965
- **DRUG:** Placebo
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT03965013
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-05
- **Primary completion:** 2019-12-14
- **Final completion:** 2019-12-14
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965013, "A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03965013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*